TrialAntimicrobial agents and chemotherapy2022
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part.
Hiroshi Mukae et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
80 papers cite itlatest 60 shown
this paperpooled ittrialcites it